A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Trial details
- Registry ID
- NCT07402876
- Drugs studied
- ICM ADX-2191 injection, Monthly ADX-2191 injection
TrialRedline tracks 27 clinical trials sponsored by Aldeyra Therapeutics, Inc.: 12 Phase 3, 1 Phase 2 / 3, 14 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT04674358 | Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution | Completed | 2021-09-12Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-03-16Day | ADX-102 Ophthalmic Solution (0.5%)Aldeyra Therapeutics, Inc. · ALDX | FDA complete response letterComplete response letter | Not specified | Open original sourceRead source excerpt{"application_number": ["NDA 216442"], "letter_date": "03/16/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Aldeyra Therapeutics, Inc.", "file_name": "CRL_NDA216442_20260316.pdf"} First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |
Names as written in the registry records.
NCT07402876 · Aldeyra Therapeutics, Inc.
Before: Dec 2026. After: Dec 2029.
NCT05717920 · Aldeyra Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Adverse Event (AE) Query Description: Incidence and severity of AEs Time frame: From Day 1 to Day 90. After: Measure: Number of Subjects With Serious Adverse Events Description: The proportion of subjects that experience at least one serious adverse event Time frame: The safety assessment period was approximately 15 weeks..
NCT05392179 · Aldeyra Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of participants with adverse events (AEs). After: Measure: Number of Subjects With Serious Adverse Events.
NCT05234554 · Aldeyra Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Ocular itching evaluated by the Subject.. After: Measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber.
NCT06685692 · Aldeyra Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 10 participants (planned). After: 4 participants (actual).
Before: Estimated. After: Actual.
Before: 31 Dec 2025. After: 18 Jun 2025.
Before: Recruiting. After: Completed.